The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Aim: The primary percutaneous procedure resulted in a significant improvement in the prognosis of myocardial infarction. However, no-reflow phenomenon restrains this benefit of the process. There are studies suggesting that soluble suppression of tumorigenicity (sST2) can be valuable in the diagnosi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Atherosclerosis and Thrombosis 2019/11/01, Vol.26(11), pp.970-978
Hauptverfasser: Somuncu, Mustafa Umut, Akgun, Tunahan, Cakır, Mustafa Ozan, Akgul, Ferit, Serbest, Nail Guven, Karakurt, Huseyin, Can, Murat, Demir, Ali Riza
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 978
container_issue 11
container_start_page 970
container_title Journal of Atherosclerosis and Thrombosis
container_volume 26
creator Somuncu, Mustafa Umut
Akgun, Tunahan
Cakır, Mustafa Ozan
Akgul, Ferit
Serbest, Nail Guven
Karakurt, Huseyin
Can, Murat
Demir, Ali Riza
description Aim: The primary percutaneous procedure resulted in a significant improvement in the prognosis of myocardial infarction. However, no-reflow phenomenon restrains this benefit of the process. There are studies suggesting that soluble suppression of tumorigenicity (sST2) can be valuable in the diagnosis and progression of heart failure and myocardial infarction. In this study, we aimed to investigate the effect of sST2 on no-reflow phenomenon in ST-elevated myocardial infarction (STEMI).Method: This study included 379 patients (258 men; mean age, 60±11 years) who underwent primary percutaneous treatment for STEMI. sST2 levels were measured from blood samples taken at admission. Patients were divided into two groups according to Thrombolysis in Myocardial Infarction(TIMI) flow grade: group 1 consists of TIMI 0,1,2, accepted as no-reflow, and group 2 consists of TIMI 3, accepted as reflow.Results: No-reflow phenomenon occurred in 60 patients (15.8%). The sST2 level was higher in the no-reflow group (14.2±4.6 vs. 11.3±5.0, p=0.003). Moreover, regression analysis indicated that diabetes mellitus, lower systolic blood pressure, multivessel vascular disease, high plaque burden, and grade 0 initial TIMI flow rate were other independent predictors of the no-reflow phenomenon in our study. Besides, when the patients were divided into high and low sST2 groups according to the cut-off value from the Receiver operating characteristics analysis, being in the high sST2 group was associated with 2.7 times increased odds for no-reflow than being in the low sST2 group.Conclusion: sST2 is one of the independent predictors of the no-reflow phenomenon in STEMI patients undergoing primary percutaneous coronary intervention.
doi_str_mv 10.5551/jat.48413
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6845696</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2211326409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4373-6df3f31c42fa7c01a54b060991860a82c659cacd5ef0f985c250d89dd27319f73</originalsourceid><addsrcrecordid>eNpVkc1uEzEQx1cIREvhwAugPcJhi7_Xe0GgqECkAhFNz5Zjj5ONHLu1d4P6GjwxTrZEcLA9nvnNf2Y0VfUao0vOOX6_1cMlkwzTJ9U5lhI1VLb0abEpKzZr5Vn1IuctQpRyTp5XZxR1ncCMn1e_lxuorzzs9QC2vol-XHmob5akXiSwvRly_T02P8H5-KtebCDEXTmh7kOBmimxL_9vD9HoZHvt63lwOpmj9zZYSOvYh3WR63c6PdQLSGYcdIA45noWUwwH7zwMkPYQDlkvq2dO-wyvHt-L6vbz1XL2tbn-8WU--3TdGEZb2gjrqKPYMOJ0axDWnK2QKINhKZCWxAjeGW0sB4dcJ7khHFnZWUtaijvX0ovqw6R7N652YE2pnrRXd1OjKupe_R8J_Uat414JybjoRBF4-yiQ4v0IeVC7PhvwfppOEYIxJYKhrqDvJtSkmHMCdyqDkTrsUJUdquMOC_vm375O5N-lFeDjBGzzoNdwAnQaeuPhKEWEwvhwHzVPIbPRSUGgfwCbPLHt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2211326409</pqid></control><display><type>article</type><title>The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</title><source>MEDLINE</source><source>J-STAGE</source><source>PubMed</source><source>EZB Electronic Journals Library</source><creator>Somuncu, Mustafa Umut ; Akgun, Tunahan ; Cakır, Mustafa Ozan ; Akgul, Ferit ; Serbest, Nail Guven ; Karakurt, Huseyin ; Can, Murat ; Demir, Ali Riza</creator><creatorcontrib>Somuncu, Mustafa Umut ; Akgun, Tunahan ; Cakır, Mustafa Ozan ; Akgul, Ferit ; Serbest, Nail Guven ; Karakurt, Huseyin ; Can, Murat ; Demir, Ali Riza</creatorcontrib><description>Aim: The primary percutaneous procedure resulted in a significant improvement in the prognosis of myocardial infarction. However, no-reflow phenomenon restrains this benefit of the process. There are studies suggesting that soluble suppression of tumorigenicity (sST2) can be valuable in the diagnosis and progression of heart failure and myocardial infarction. In this study, we aimed to investigate the effect of sST2 on no-reflow phenomenon in ST-elevated myocardial infarction (STEMI).Method: This study included 379 patients (258 men; mean age, 60±11 years) who underwent primary percutaneous treatment for STEMI. sST2 levels were measured from blood samples taken at admission. Patients were divided into two groups according to Thrombolysis in Myocardial Infarction(TIMI) flow grade: group 1 consists of TIMI 0,1,2, accepted as no-reflow, and group 2 consists of TIMI 3, accepted as reflow.Results: No-reflow phenomenon occurred in 60 patients (15.8%). The sST2 level was higher in the no-reflow group (14.2±4.6 vs. 11.3±5.0, p=0.003). Moreover, regression analysis indicated that diabetes mellitus, lower systolic blood pressure, multivessel vascular disease, high plaque burden, and grade 0 initial TIMI flow rate were other independent predictors of the no-reflow phenomenon in our study. Besides, when the patients were divided into high and low sST2 groups according to the cut-off value from the Receiver operating characteristics analysis, being in the high sST2 group was associated with 2.7 times increased odds for no-reflow than being in the low sST2 group.Conclusion: sST2 is one of the independent predictors of the no-reflow phenomenon in STEMI patients undergoing primary percutaneous coronary intervention.</description><identifier>ISSN: 1340-3478</identifier><identifier>EISSN: 1880-3873</identifier><identifier>DOI: 10.5551/jat.48413</identifier><identifier>PMID: 30996145</identifier><language>eng</language><publisher>Japan: Japan Atherosclerosis Society</publisher><subject>Biomarkers - blood ; Female ; Follow-Up Studies ; Humans ; In-hospital mortality ; Inflammation ; Interleukin-1 Receptor-Like 1 Protein - blood ; Male ; Middle Aged ; Myocardial infarction ; No-Reflow Phenomenon - blood ; No-Reflow Phenomenon - diagnosis ; No-Reflow Phenomenon - etiology ; No-reflow-phenomenon ; Original ; Percutaneous Coronary Intervention - adverse effects ; Prognosis ; Risk Assessment ; ROC Curve ; soluble ST2 ; ST Elevation Myocardial Infarction - surgery</subject><ispartof>Journal of Atherosclerosis and Thrombosis, 2019/11/01, Vol.26(11), pp.970-978</ispartof><rights>2019 This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.</rights><rights>2019 Japan Atherosclerosis Society 2019</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4373-6df3f31c42fa7c01a54b060991860a82c659cacd5ef0f985c250d89dd27319f73</citedby><cites>FETCH-LOGICAL-c4373-6df3f31c42fa7c01a54b060991860a82c659cacd5ef0f985c250d89dd27319f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6845696/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6845696/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1883,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30996145$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Somuncu, Mustafa Umut</creatorcontrib><creatorcontrib>Akgun, Tunahan</creatorcontrib><creatorcontrib>Cakır, Mustafa Ozan</creatorcontrib><creatorcontrib>Akgul, Ferit</creatorcontrib><creatorcontrib>Serbest, Nail Guven</creatorcontrib><creatorcontrib>Karakurt, Huseyin</creatorcontrib><creatorcontrib>Can, Murat</creatorcontrib><creatorcontrib>Demir, Ali Riza</creatorcontrib><title>The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</title><title>Journal of Atherosclerosis and Thrombosis</title><addtitle>JAT</addtitle><description>Aim: The primary percutaneous procedure resulted in a significant improvement in the prognosis of myocardial infarction. However, no-reflow phenomenon restrains this benefit of the process. There are studies suggesting that soluble suppression of tumorigenicity (sST2) can be valuable in the diagnosis and progression of heart failure and myocardial infarction. In this study, we aimed to investigate the effect of sST2 on no-reflow phenomenon in ST-elevated myocardial infarction (STEMI).Method: This study included 379 patients (258 men; mean age, 60±11 years) who underwent primary percutaneous treatment for STEMI. sST2 levels were measured from blood samples taken at admission. Patients were divided into two groups according to Thrombolysis in Myocardial Infarction(TIMI) flow grade: group 1 consists of TIMI 0,1,2, accepted as no-reflow, and group 2 consists of TIMI 3, accepted as reflow.Results: No-reflow phenomenon occurred in 60 patients (15.8%). The sST2 level was higher in the no-reflow group (14.2±4.6 vs. 11.3±5.0, p=0.003). Moreover, regression analysis indicated that diabetes mellitus, lower systolic blood pressure, multivessel vascular disease, high plaque burden, and grade 0 initial TIMI flow rate were other independent predictors of the no-reflow phenomenon in our study. Besides, when the patients were divided into high and low sST2 groups according to the cut-off value from the Receiver operating characteristics analysis, being in the high sST2 group was associated with 2.7 times increased odds for no-reflow than being in the low sST2 group.Conclusion: sST2 is one of the independent predictors of the no-reflow phenomenon in STEMI patients undergoing primary percutaneous coronary intervention.</description><subject>Biomarkers - blood</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>In-hospital mortality</subject><subject>Inflammation</subject><subject>Interleukin-1 Receptor-Like 1 Protein - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial infarction</subject><subject>No-Reflow Phenomenon - blood</subject><subject>No-Reflow Phenomenon - diagnosis</subject><subject>No-Reflow Phenomenon - etiology</subject><subject>No-reflow-phenomenon</subject><subject>Original</subject><subject>Percutaneous Coronary Intervention - adverse effects</subject><subject>Prognosis</subject><subject>Risk Assessment</subject><subject>ROC Curve</subject><subject>soluble ST2</subject><subject>ST Elevation Myocardial Infarction - surgery</subject><issn>1340-3478</issn><issn>1880-3873</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc1uEzEQx1cIREvhwAugPcJhi7_Xe0GgqECkAhFNz5Zjj5ONHLu1d4P6GjwxTrZEcLA9nvnNf2Y0VfUao0vOOX6_1cMlkwzTJ9U5lhI1VLb0abEpKzZr5Vn1IuctQpRyTp5XZxR1ncCMn1e_lxuorzzs9QC2vol-XHmob5akXiSwvRly_T02P8H5-KtebCDEXTmh7kOBmimxL_9vD9HoZHvt63lwOpmj9zZYSOvYh3WR63c6PdQLSGYcdIA45noWUwwH7zwMkPYQDlkvq2dO-wyvHt-L6vbz1XL2tbn-8WU--3TdGEZb2gjrqKPYMOJ0axDWnK2QKINhKZCWxAjeGW0sB4dcJ7khHFnZWUtaijvX0ovqw6R7N652YE2pnrRXd1OjKupe_R8J_Uat414JybjoRBF4-yiQ4v0IeVC7PhvwfppOEYIxJYKhrqDvJtSkmHMCdyqDkTrsUJUdquMOC_vm375O5N-lFeDjBGzzoNdwAnQaeuPhKEWEwvhwHzVPIbPRSUGgfwCbPLHt</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Somuncu, Mustafa Umut</creator><creator>Akgun, Tunahan</creator><creator>Cakır, Mustafa Ozan</creator><creator>Akgul, Ferit</creator><creator>Serbest, Nail Guven</creator><creator>Karakurt, Huseyin</creator><creator>Can, Murat</creator><creator>Demir, Ali Riza</creator><general>Japan Atherosclerosis Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20191101</creationdate><title>The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</title><author>Somuncu, Mustafa Umut ; Akgun, Tunahan ; Cakır, Mustafa Ozan ; Akgul, Ferit ; Serbest, Nail Guven ; Karakurt, Huseyin ; Can, Murat ; Demir, Ali Riza</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4373-6df3f31c42fa7c01a54b060991860a82c659cacd5ef0f985c250d89dd27319f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biomarkers - blood</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>In-hospital mortality</topic><topic>Inflammation</topic><topic>Interleukin-1 Receptor-Like 1 Protein - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial infarction</topic><topic>No-Reflow Phenomenon - blood</topic><topic>No-Reflow Phenomenon - diagnosis</topic><topic>No-Reflow Phenomenon - etiology</topic><topic>No-reflow-phenomenon</topic><topic>Original</topic><topic>Percutaneous Coronary Intervention - adverse effects</topic><topic>Prognosis</topic><topic>Risk Assessment</topic><topic>ROC Curve</topic><topic>soluble ST2</topic><topic>ST Elevation Myocardial Infarction - surgery</topic><toplevel>online_resources</toplevel><creatorcontrib>Somuncu, Mustafa Umut</creatorcontrib><creatorcontrib>Akgun, Tunahan</creatorcontrib><creatorcontrib>Cakır, Mustafa Ozan</creatorcontrib><creatorcontrib>Akgul, Ferit</creatorcontrib><creatorcontrib>Serbest, Nail Guven</creatorcontrib><creatorcontrib>Karakurt, Huseyin</creatorcontrib><creatorcontrib>Can, Murat</creatorcontrib><creatorcontrib>Demir, Ali Riza</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Atherosclerosis and Thrombosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Somuncu, Mustafa Umut</au><au>Akgun, Tunahan</au><au>Cakır, Mustafa Ozan</au><au>Akgul, Ferit</au><au>Serbest, Nail Guven</au><au>Karakurt, Huseyin</au><au>Can, Murat</au><au>Demir, Ali Riza</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</atitle><jtitle>Journal of Atherosclerosis and Thrombosis</jtitle><addtitle>JAT</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>26</volume><issue>11</issue><spage>970</spage><epage>978</epage><pages>970-978</pages><issn>1340-3478</issn><eissn>1880-3873</eissn><abstract>Aim: The primary percutaneous procedure resulted in a significant improvement in the prognosis of myocardial infarction. However, no-reflow phenomenon restrains this benefit of the process. There are studies suggesting that soluble suppression of tumorigenicity (sST2) can be valuable in the diagnosis and progression of heart failure and myocardial infarction. In this study, we aimed to investigate the effect of sST2 on no-reflow phenomenon in ST-elevated myocardial infarction (STEMI).Method: This study included 379 patients (258 men; mean age, 60±11 years) who underwent primary percutaneous treatment for STEMI. sST2 levels were measured from blood samples taken at admission. Patients were divided into two groups according to Thrombolysis in Myocardial Infarction(TIMI) flow grade: group 1 consists of TIMI 0,1,2, accepted as no-reflow, and group 2 consists of TIMI 3, accepted as reflow.Results: No-reflow phenomenon occurred in 60 patients (15.8%). The sST2 level was higher in the no-reflow group (14.2±4.6 vs. 11.3±5.0, p=0.003). Moreover, regression analysis indicated that diabetes mellitus, lower systolic blood pressure, multivessel vascular disease, high plaque burden, and grade 0 initial TIMI flow rate were other independent predictors of the no-reflow phenomenon in our study. Besides, when the patients were divided into high and low sST2 groups according to the cut-off value from the Receiver operating characteristics analysis, being in the high sST2 group was associated with 2.7 times increased odds for no-reflow than being in the low sST2 group.Conclusion: sST2 is one of the independent predictors of the no-reflow phenomenon in STEMI patients undergoing primary percutaneous coronary intervention.</abstract><cop>Japan</cop><pub>Japan Atherosclerosis Society</pub><pmid>30996145</pmid><doi>10.5551/jat.48413</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1340-3478
ispartof Journal of Atherosclerosis and Thrombosis, 2019/11/01, Vol.26(11), pp.970-978
issn 1340-3478
1880-3873
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6845696
source MEDLINE; J-STAGE; PubMed; EZB Electronic Journals Library
subjects Biomarkers - blood
Female
Follow-Up Studies
Humans
In-hospital mortality
Inflammation
Interleukin-1 Receptor-Like 1 Protein - blood
Male
Middle Aged
Myocardial infarction
No-Reflow Phenomenon - blood
No-Reflow Phenomenon - diagnosis
No-Reflow Phenomenon - etiology
No-reflow-phenomenon
Original
Percutaneous Coronary Intervention - adverse effects
Prognosis
Risk Assessment
ROC Curve
soluble ST2
ST Elevation Myocardial Infarction - surgery
title The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T05%3A42%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Elevated%20Soluble%20ST2%20Predicts%20No-Reflow%20Phenomenon%20in%20ST-Elevation%20Myocardial%20Infarction%20Undergoing%20Primary%20Percutaneous%20Coronary%20Intervention&rft.jtitle=Journal%20of%20Atherosclerosis%20and%20Thrombosis&rft.au=Somuncu,%20Mustafa%20Umut&rft.date=2019-11-01&rft.volume=26&rft.issue=11&rft.spage=970&rft.epage=978&rft.pages=970-978&rft.issn=1340-3478&rft.eissn=1880-3873&rft_id=info:doi/10.5551/jat.48413&rft_dat=%3Cproquest_pubme%3E2211326409%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2211326409&rft_id=info:pmid/30996145&rfr_iscdi=true